Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor
Titel:
Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor
Auteur:
Salles, Gilles Chen, Jenny M. H. Zhang, Ina Kerbauy, Fabio Wu, James J. Wade, Sally W. Nunes, Ana Feng, Chaoling Kloos, Ioana Peng, Weimin Snider, Julia T. Maciel, Dylan Chan, Keith Keeping, Sam Shah, Bijal